NO20063858L - Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer - Google Patents
Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformerInfo
- Publication number
- NO20063858L NO20063858L NO20063858A NO20063858A NO20063858L NO 20063858 L NO20063858 L NO 20063858L NO 20063858 A NO20063858 A NO 20063858A NO 20063858 A NO20063858 A NO 20063858A NO 20063858 L NO20063858 L NO 20063858L
- Authority
- NO
- Norway
- Prior art keywords
- cyclodextrins
- beta
- obtaining
- dosage forms
- liquid dosage
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 | |
| PCT/IB2005/000100 WO2005082416A2 (en) | 2004-01-30 | 2005-01-17 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063858L true NO20063858L (no) | 2006-10-19 |
Family
ID=34910697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063858A NO20063858L (no) | 2004-01-30 | 2006-08-29 | Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (ko) |
| EP (1) | EP1713504B1 (ko) |
| JP (1) | JP5021318B2 (ko) |
| KR (1) | KR100834232B1 (ko) |
| CN (1) | CN101090735A (ko) |
| AR (2) | AR047469A1 (ko) |
| AU (1) | AU2005216709B2 (ko) |
| BR (1) | BRPI0506496B8 (ko) |
| CA (1) | CA2554346C (ko) |
| CO (1) | CO5700794A2 (ko) |
| CY (1) | CY1119188T1 (ko) |
| DK (1) | DK1713504T3 (ko) |
| ES (1) | ES2638113T3 (ko) |
| HU (1) | HUE034099T2 (ko) |
| IL (1) | IL176676A0 (ko) |
| LT (1) | LT1713504T (ko) |
| NO (1) | NO20063858L (ko) |
| NZ (1) | NZ548236A (ko) |
| PL (1) | PL1713504T3 (ko) |
| PT (1) | PT1713504T (ko) |
| RU (1) | RU2332997C2 (ko) |
| SI (1) | SI1713504T1 (ko) |
| TW (1) | TW200524632A (ko) |
| WO (1) | WO2005082416A2 (ko) |
| ZA (1) | ZA200605148B (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852716C (en) * | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| AU2014292086B2 (en) * | 2013-07-19 | 2019-08-08 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| US11160809B2 (en) | 2017-04-10 | 2021-11-02 | Chase Therapeutics Corporation | NK1-antagonist combination and method for treating synucleinopathies |
| BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
| EP3923916A4 (en) * | 2019-02-15 | 2022-12-21 | Saol International Development Ltd. | INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| DE69208877T2 (de) | 1991-05-31 | 1996-07-25 | Pfizer | Chinuclidinderivate |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5886009A (en) | 1992-11-12 | 1999-03-23 | Pfizer Inc. | Quinuclidine derivative as a substance P antagonist |
| US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| WO2000012137A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| AU5975700A (en) | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| AU2002254309B2 (en) * | 2001-03-20 | 2006-02-02 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CN1529600A (zh) * | 2001-07-20 | 2004-09-15 | �Ʒ� | Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途 |
| AR038576A1 (es) | 2002-02-22 | 2005-01-19 | Pharmacia Corp | Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| JP2007519701A (ja) | 2004-01-30 | 2007-07-19 | ファイザー・プロダクツ・インク | 麻酔回復を改善するためのｎｋ−１受容体拮抗剤 |
| MXPA06008648A (es) | 2004-01-30 | 2006-09-04 | Pfizer Prod Inc | Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion. |
| JP2007519710A (ja) | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | １−（２Ｓ，３Ｓ）−２−ベンズヒドリル−Ｎ−（５−ｔｅｒｔ−ブチル−２−メトキシベンジル）キヌクリジン−３−アミンの製造方法 |
-
2005
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en active Application Filing
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en active Active
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko active IP Right Grant
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja active Active
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en active Active
- 2005-01-17 CA CA002554346A patent/CA2554346C/en active Active
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en unknown
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es active Active
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20063858L (no) | Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer | |
| NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
| NO20052130L (no) | Sterk inhibitor for HCV-serin-protease | |
| WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| EP1340755A4 (en) | AGENT WITH EFFECT AGAINST HELICOBACTER | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| WO2009007137A3 (en) | Pharmaceutical composition for topical application of poorly soluble compounds | |
| ES2344909T3 (es) | Nuevas combinaciones de un antagonista del receptor 5-ht3 con racecadotril o dexecanotril. | |
| NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
| DE50109650D1 (de) | Topische behandlung bei der mastalgie | |
| NO323556B1 (no) | Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter. | |
| WO2009038411A3 (en) | Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety | |
| TW200616614A (en) | A pharmaceutical composition for treating spinocerebellar ataxia | |
| NO20081736L (no) | Antitumormidler | |
| WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine | |
| TW200508227A (en) | [4-(3-aminomethylphenyl)piperidin-1-yl]-[5-(2-fluorophenylethynyl)furan-2-yl]-methanone as an inhibitor of mast cell tryptase | |
| RU2446158C2 (ru) | Замещенные изоиндолы в качестве ингибиторов васе и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |